RxDoctor Payments Data

Hibba Tul Rehman, MD

Hematology & Oncology · Burlington, VTNPI 1861773913

Payments from drug & device makers

What this record shows

This record is dominated by education: $80 of the $127 with a category attached, or 63.0%. 5 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 40.4% of the total. 2025 is the largest year on record at $47, 4.3 times the $11 reported in 2019.

$127in general payments, 2019–2025

Across 7 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$51
  • Daiichi Sankyo Inc.$30
  • Epizyme, Inc.$18
  • Caris MPI, Inc.$17
  • Pfizer$11
$108,057in research payments, 2019–2025

Across 30 payments — averaging $3601.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$68K
  • Eli Lilly$40K

What the payments were for

  • Food & beverage$4737%
  • Education$8063%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few hematology & oncology providers in Vermontto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$87,310
Medicare patients
204
Services billed
866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumakrasSotorasib17$325,450
BraftoviEncorafenib24$287,280
LenvimaLenvatinib Mesylate11$250,034
MektoviBinimetinib27$244,038
LorbrenaLorlatinib19$225,487
EliquisApixaban37$23,756
Tacrolimus20$1,552
Oxycodone Hcl19$1,311
Dexamethasone54$768
Anastrozole17$535
Prochlorperazine Maleate39$456
Levothyroxine Sodium50$408
Morphine Sulfate ErMorphine Sulfate20$337
Ondansetron OdtOndansetron37$336
Omeprazole20$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerLorbrena, Eliquis$11$249,24356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Vermonton file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →